Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 LongTerm Study of REL-1017 in Major Depressive Disorder

Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment

Long-term dosing with REL-1017 was well-tolerated, with low rates of adverse events and discontinuations due to adverse events, and no new safety signals were detected

See more here